About a month after completing a reorganization to increase its specialty pharmaceutical business, Apothecary By Design has made its first acquisition.

The Portland-based company announced Tuesday that it has acquired Healy Pharmacy in metro Chicago. The purchase price was not disclosed.

Both pharmacies focus on specialty prescriptions to treat people with chronic or complicated conditions such as infertility, multiple sclerosis, Hepatitis C and rheumatoid arthritis.

“Healy and Apothecary by Design are deeply committed to providing high-quality patient care,” said Mark McAuliffe, chief executive of Apothecary By Design, in a press release. “Together, our pharmacies will be able to exchange best practices and deliver even better outcomes.”

ABD and Healy specialize in infertility treatment, serving complementary geographic markets with little overlap, he said. In addition, the partnership blends unique areas of expertise, such as Healy’s strength in oncology and ABD’s experience in infectious and inflammatory diseases.

Healy Pharmacy, based in Warrenville, Illinois, has been an independent specialty pharmacy for about 30 years with annual revenues of roughly $35 million. No staffing changes are planned as a result of the acquisition, according to the release.

On Feb. 8, Apothecary By Design announced it was selling its retail pharmacy division on Marginal Way to a local partnership that included two employees. That transaction has concluded and the pharmacy has been renamed Coastal Pharmacy & Wellness. The sale was intended to free the specialty services division of the company to pursue its own growth and create a regional network of specialty pharmacies.

“This definitely allows us to focus on the specialty part of the business, where the growth is,” McAuliffe told the Press Herald in an interview. “We will be looking to expand and acquire additional specialty pharmacies.”

In September, BelHealth Investment Partners, a New York private equity firm, acquired a controlling interest in Apothecary by Design, to position it as the corporate parent for future acquisitions. The investment firm is especially interested in establishing itself in the $2 billion-a-year-and-growing fertility industry.

BelHealth typically invests $20 million to $50 million per company across three health care segments: services, products and distribution. It provides capital to rapidly grow portfolio companies with the goal of selling them within three to five years, according to its website.

Only subscribers are eligible to post comments. Please subscribe or to participate in the conversation. Here’s why.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.